Campos Cécile, Perrey Antoine, Lambert Céline, Pereira Bruno, Goutte Marion, Dubois Anne, Goutorbe Felix, Dapoigny Michel, Bommelaer Gilles, Hordonneau Constance, Buisson Anthony
Service d'Hépato-Gastro Entérologie, Inserm, 3iHP, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
Service de Radiologie, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
Dig Dis Sci. 2017 Jun;62(6):1628-1636. doi: 10.1007/s10620-017-4572-4. Epub 2017 Apr 11.
Medical therapy efficacy remains controversial in stricturing Crohn's disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making.
To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn's disease.
In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI).
Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn's disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37-11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01-1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04-1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64-19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40-0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03-0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01-0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005-0.97], p = 0.047) were associated with short-term clinical failure.
Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn's disease.
在狭窄型克罗恩病中,药物治疗的疗效仍存在争议。横断面成像,尤其是磁共振成像,已被认为对指导治疗决策非常有帮助。
评估接受药物治疗的狭窄型克罗恩病患者的治疗效果及治疗失败的预测因素。
在这项回顾性研究中,治疗失败定义为导致手术或内镜治疗、住院、治疗中断或额外治疗的症状性狭窄,短期临床反应定义为由两名医生评估的临床改善。两名放射科医生独立分析开始药物治疗前的55次横断面成像检查(33次磁共振成像和22次CT扫描)。结果以风险比(HR)或比值比(OR)及95%置信区间(95%CI)表示。
84例患者中,60个月内的治疗失败率为66.6%。多因素分析显示,40岁后诊断为克罗恩病(HR 3.9,95%CI[1.37 - 11.2],p = 0.011)、狭窄管腔直径小(HR 1.34,95%CI[1.01 - 1.80],p = 0.046)、狭窄管壁厚度增加(HR 1.23,95%CI[1.04 - 1.46],p = 0.013)和伴有脓肿的瘘管(HR 5.63,95%CI[1.64 - 19.35],p = 0.00)与治疗失败相关,而抗TNF联合治疗(HR 0.17,95%CI[0.40 - 0.71],p = 0.015)可预防治疗失败。考虑108个治疗疗程,短期临床反应率为65.7%。多因素分析显示,男性(OR 0.15,95%CI[0.03 - 0.64],p = 0.011)、伴有脓肿的瘘管(OR 0.09,95%CI[0.01 - 0.77],p = 0.028)和梳状征(OR 0.23,95%CI[0.005 - 0.97],p =)与短期临床失败相关。
抗TNF联合治疗似乎可预防治疗失败,应系统地进行横断面成像以帮助狭窄型克罗恩病的药物治疗管理。